RMA-COVID-19: Respiratory Muscle Assesment in COVID-patients Without Hospitalization

Sponsor
RWTH Aachen University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06105450
Collaborator
(none)
25
1
12
2.1

Study Details

Study Description

Brief Summary

Fatigue and exercise intolerance after survived COVID-19-infection might be related to weakness of the respiratory muscles. The aim of the project is to measure respiratory muscle function and strength in our respiratory physiology laboratory in patients who were not hospitalized during the acute COVID-19-infection but still complain of different persistent symptoms including exertional dyspnea and fatigue.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Comprehensive assessment of respiratory muscle function.

Detailed Description

Since the beginning of the COVID pandemic, more and more recovered patients have a number of persistent symptoms including exertional dyspnea and fatigue even months after recovering from acute coronavirus disease 2019 (COVID-19). These symptoms often cannot be explained because routine clinical diagnoses, including extensive cardiac and pulmonary examinations, do not reveal any relevant abnormalities.

In our previous study (Regmi et al) with 50 patients formerly hospitalized due to acute COVID-19 infection, it was shown that diaphragm muscle weakness contributes to persistent exertional dyspnea about one year after hospitalization for COVID-19, regardless of mechanical ventilation. Additionally, the severity of exertional dyspnea correlated with the extent of diaphragmatic weakness.

Since laboratory findings, pulmonary function tests and cardiological routine examinations did not reveal any significant impairments, this was the first time that a potential pathophysiological correlate is objectively associated with dyspnea in long COVID-19 syndrome. The results of our study were clinically relevant because the persistent symptom burden in patients after surviving COVID-19 infection remains very high. In addition diaphragm training presents itself as a potential therapeutic target, since in other diseases such as COPD, such training has been shown to improve the symptoms. Therefore, the investigators believe that the results provide important perspectives, both for the pathophysiological understanding and for the potential treatment of persistent exertional dyspnea in patients.

However, a considerable gap exists here: a significant number of patients who suffer from an acute COVID-19 infection but do not have a severe course during the initial infection, so that hospitalization is not necessary, still complain of different persistent symptoms. Here, too, despite an extensive cardiopulmonary work-up, there is a lack of a sufficient explanation of the lasting complaints. It is precisely in these patients that a possible role of diaphragmatic weakness on the symptoms is yet to be investigated using already established gold standard techniques.

Study Design

Study Type:
Observational
Anticipated Enrollment :
25 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Potential Role of Diaphragmatic Muscle Weakness as a Cause of Persistent Exertional Dyspnea in Patients With COVID-19 Disease Without Hospitalization
Anticipated Study Start Date :
Dec 1, 2023
Anticipated Primary Completion Date :
Dec 1, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Outcome Measures

Primary Outcome Measures

  1. Twitch transdiaphragmatic pressure in response to supramaximal magnetic stimulation of the phrenic nerve roots [1 year]

    Recording of twitch transdiaphragmatic pressure (Unit: Pressure in cmH2O)

  2. Respiratory mouth pressures [1 year]

    Measurement of respiratory (inspiratory and expiratory) mouth pressures (Unit: Pressure in cmH2O)

Secondary Outcome Measures

  1. Diaphragm ultrasound [1 year]

    Comprehensive evaluation of diaphragm excursion (amplitude during tidal breathing, sniff maneuver and maximal inspiration in cm, corresponding velocity in cm/sec, respectively) and thickening on ultrasound (thickness at functional residual capacity, at total lung capactiy in cm), Markers of Diaphragm excursion and thickening will be combined to classify diaphragm function as normal, mildly, moderately or severly impaired.

  2. Exercise intolerance [1 year]

    Comprehensive evaluation of symptoms (breathlesness based on NYHA class, on a visual scale ranging from 1-10, respectively) and exercise capacity (6 minute walking distance). These measurements will be combined to classifiy patients as presenting with exercise intolerance or no exercise intolerance.

  3. Lung function [1 year]

    Comprehensive assessment of lung function by bodyplethysmography (most importantly forced vital capacity, forced expiratory volume after 1 second, intrathoracic gas volume, residual volume) and capillary blood gas analysis (most importantly pO2 in mmHG and pCO2 in mmHG). These measurements will be combined to classify patients as showing normal, restrictive, obstructive lung function impairment, as being hypoxic, hypercapnic, respectively.

  4. EMG [1 year]

    Diaphragm and accessory respiratory muscle electromyography

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with COVID-19 infection without hospitalization during the acute infection (n=25)

  • Patients aged at least 18 years, who are mentally and physically able to consent and participate into the study

Exclusion Criteria:
  • Clinically pre-established cardiovascular disease or other pulmonary diseases which might lead to exertional dyspnea (systolic heart failure, COPD).

  • Body-mass-index (BMI) >40

  • Expected absence of active participation of the patient in study-related measurements

  • Alcohol or drug abuse

  • Metal implant in the body that is not MRI compatible (NON MRI compatible pacemaker, implantable defibrillator, cervical implants, e.g. brain pacemakers etc.)

  • Slipped disc

  • Epilepsy

  • Bound to a wheel chair

Contacts and Locations

Locations

Site City State Country Postal Code
1 Jens Spiesshoefer Aachen NRW Germany

Sponsors and Collaborators

  • RWTH Aachen University

Investigators

  • Study Director: Michael Dreher, Professor, RWTH Aachen University
  • Principal Investigator: Jens Spiesshoefer, MD, RWTH Aachen University
  • Study Chair: Binaya Regmi, MD, RWTH Aachen University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Jens Spießhöfer, Principal Investigator, RWTH Aachen University
ClinicalTrials.gov Identifier:
NCT06105450
Other Study ID Numbers:
  • 23-296
First Posted:
Oct 27, 2023
Last Update Posted:
Nov 1, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Jens Spießhöfer, Principal Investigator, RWTH Aachen University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 1, 2023